Suppr超能文献

微小RNA-155通过增强对稳态γc细胞因子的反应性,增强淋巴细胞充足宿主中CD8 + T细胞的抗肿瘤活性。

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

作者信息

Ji Yun, Wrzesinski Claudia, Yu Zhiya, Hu Jinhui, Gautam Sanjivan, Hawk Nga V, Telford William G, Palmer Douglas C, Franco Zulmarie, Sukumar Madhusudhanan, Roychoudhuri Rahul, Clever David, Klebanoff Christopher A, Surh Charles D, Waldmann Thomas A, Restifo Nicholas P, Gattinoni Luca

机构信息

Experimental Transplantation and Immunology Branch and

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

出版信息

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):476-81. doi: 10.1073/pnas.1422916112. Epub 2014 Dec 29.

Abstract

Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.

摘要

淋巴细胞清除方案在过继性免疫治疗前使用,通过去除内源性稳态“细胞因子库”来增强转移T细胞的抗肿瘤功效。然而,这些预处理方式常常伴有严重的毒性。我们发现,微小RNA-155(miR-155)能使肿瘤特异性CD8(+) T细胞在淋巴细胞充足的宿主中介导显著的抗肿瘤反应,且这种反应不会因免疫消融而增强。miR-155增强了T细胞对有限量稳态γc细胞因子的反应性,导致细胞收缩延迟并持续产生细胞因子。miR-155抑制了肌醇5-磷酸酶Ship1的表达,Ship1是丝氨酸-苏氨酸蛋白激酶Akt的抑制剂,同时也抑制了信号转导及转录激活因子5(Stat5)的多个负调节因子,包括细胞因子信号抑制因子1(Socs1)和蛋白酪氨酸磷酸酶Ptpn2。组成型活性Stat5a的表达重现了miR-155赋予的生存优势,而组成型Akt激活则促进了持续的效应器功能。我们的结果表明,在肿瘤特异性T细胞中过表达miR-155可用于以细胞内在方式提高过继性免疫治疗的有效性,而无需进行危及生命的淋巴细胞清除操作。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验